Aurion Biotech Achieves All Primary, Secondary, and Exploratory Endpoints in AURN001 Phase 1/2 CLARA Trial at 12 Months
Data strongly supports advancing high dose AURN001 regenerative cell therapy for patients with corneal endothelial disease to pivotal Phase 3 trial in H1 2026 SEATTLE & CAMBRIDGE, Mass. & TOKYO — Aurion Biotech, a clinical-stage regenerative medicine company
(Financial Post, 2025-10-18T18:33:57Z)